Patient consent management rarely gets the spotlight in market access conversations. It doesn’t have the urgency of coverage denials or the visibility of clinical delays. But based on what Claritas Rx is seeing, it’s quietly one of the most consequential and most overlooked risk points in the patient journey, according to Loan Villaverde, Senior Director of Data Strategy at Claritas Rx.
In a recent webinar, Villaverde shared a telling example: a patient’s therapy start was delayed by more than two weeks. Not because of a clinical issue. Not because of an insurance holdup. The patient’s consent status was simply recorded differently in the hub system than in the specialty pharmacy system, and no one caught the mismatch until the patient called in, confused about why treatment hadn’t started.
It’s a paperwork problem with a direct line to access outcomes.
Why Consent Has Gotten So Complicated
Villaverde outlined four layers of complexity that stack on top of each other. They usually stay invisible until something breaks: an unreachable patient, an audit gap, or a regulatory inquiry.
1. State-level regulation. States like California, Texas, New York, and Illinois each layer their own rules on top of federal HIPAA standards. California’s CMIA caps authorization at one year and requires patient sign-off for disclosures HIPAA would otherwise permit. SB 81 classifies immigration status and place of birth as medical information, categories HIPAA doesn’t even touch. Illinois’s BIPA adds biometric data protections with mandatory breach reporting, and Texas’s TMRPA shortens patient record-access timelines to 15 days, compared to HIPAA’s 30, with lower breach-notification thresholds. A consent approach built for one state can leave real gaps in another.
2. Channels and modalities. Verbal consent on a recorded call, a digital portal opt-in, and written authorization at hub enrollment can all carry different legal weight. Teams need clarity on which method is valid for which channel. Without it, the gap only surfaces during an audit, which is the worst possible time to find out. Both wet and electronic signatures are valid under HIPAA, but e-signatures come with four requirements: identity verification, affirmative consent to transact electronically, retrievability of both signed and unsigned copies, and a full audit trail (who, when, how, and supporting metadata) retained for at least six years.
3. Sensitive data categories. Substance use disorder records fall under 42 CFR Part 2, which requires nine consent elements beyond standard HIPAA forms. HIV/AIDS status carries additional state-level requirements in many places. Mental health and psychotherapy notes require a separate authorization form under HIPAA itself. These categories can coexist within a single patient record, so consent logic has to be dynamic at the record level rather than a one-time checkbox at enrollment.
4. Instant revocability. Under HIPAA, a patient can revoke consent at any time, effective immediately, across every system. Any lag in that propagation is real compliance exposure.
Where the Gaps Actually Show Up
Walking through a typical patient journey, Villaverde pointed to recurring failure points:
- At the hub: consent is captured once at intake but rarely re-verified as circumstances change, such as a patient turning 18 or a consent term expiring.
- At the specialty pharmacy: handoff blind spots are common. Forms have arrived faxed upside down or illegible, with no notification process or follow-up in place to catch it.
- With field reimbursement teams: limited visibility forces reps to default to the most conservative assumptions, which constrains the support they can offer.
- In copay programs: enrollment consent, marketing consent, and HIPAA consent are often distinct and easily conflated, creating friction and unclear status.
In a case study of oral and infused oncology therapies, Claritas Rx found that a quarter to a third of a manufacturer’s patient population engages with two or more channel partners over the course of treatment. In some cases, a single patient journey touches six to eight distinct data sources.1 More partners mean more handoffs, and more handoffs mean more places for consent status to fall out of sync.
The Fix: A Centralized Consent Clearinghouse
Rather than consent living separately across hubs, specialty pharmacies, and copay programs, Claritas Rx’s Consent Clearinghouse™ approach routes everything into a single governed record. This clearinghouse layers on top of existing systems instead of replacing them.
The model delivers three things:
- Real-time synchronization, so a revocation is honored immediately everywhere
- HIPAA-compliant de-identification, including expert determination methods, which matters especially for rare disease populations where small cohort sizes make de-identification harder
- A complete audit trail that supports regulatory review without exposing identifiable data
The Payoff, By Stakeholder
Closing consent gaps isn’t a single-team win. Villaverde named three groups who benefit directly:
- Manufacturers get faster, compliant access to real-world data. When consent status is governed centrally, regulatory and market access teams aren’t stuck waiting on data that’s technically available but unusable.
- Specialty pharmacies and field teams get cleaner data, fewer handoff errors, and fewer legal reviews.
- Patients get real transparency and control over their own data. Claritas Rx’s analysis found consent-aligned populations see 12 to 40% higher fill rates and up to 11% higher refill rates compared to non-consent populations1, a reminder that trust and adherence are directly linked.
Migration Without the Risk
A common concern is what happens to existing consent data when a manufacturer moves to a centralized clearinghouse. Villaverde was clear that a failed migration can be worse than a fragmented status quo, so the process starts with a full inventory of existing consent fields, forms, and logic. This determines what data exists, what’s missing, and how it can be integrated. From there, onboarding is phased by source, typically starting with hubs and validating and reconciling before layering in specialty pharmacies. Existing hub and SP platforms keep operating as they are, and the clearinghouse simply sits on top as a governance layer.
On timeline, the platform side moves quickly. Visibility into a given source’s consent gap appears shortly after that source is onboarded. The real variable is partner behavior: how fast hubs and SPs adapt their own processes to close the loop. Programs that treat partner onboarding as a day-one priority, with clear ownership and timelines, tend to close the gap fastest.
The Bottom Line
Every patient sitting in a consent gap is a patient whose treatment is on pause for reasons that have nothing to do with their diagnosis. Villaverde’s point was that this is fixable, and the manufacturers already doing it are the ones prioritizing consent.
If you’d like to go deeper on this topic, watch the full webinar featuring Villaverde.
—
1. Villaverde, L. (2026). Transforming data aggregation in oncology, specialty, and rare disease: Breaking free from the black-box data to unlock transparent, actionable insights across complex patient journeys [White paper]. Claritas Rx.
